Natera
NTRA Large CapHealthcare · Diagnostics & Research
Updated: Jul 5, 2026, 22:19 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and
Natera Stock at a Glance
Natera (NTRA) is currently trading at $279.32 with a market capitalization of $40B. The 52-week range spans from $131.81 to $279.63; the current price is 0.1% below the yearly high. Year-over-year revenue growth stands at +38.8%.
💰 Dividend
Natera currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
21 analysts rate Natera (NTRA) on consensus: Strong Buy. The average price target is $264.57, implying -5.28% from the current price. Analyst price targets range from $193.00 to $310.00.
Natera: The Investment Case in Detail
Natera (NTRA) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Top-line momentum is unusually strong with revenue expanding 38.8% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 65.07%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
The Bear Case
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.
Smart-Money Signal
On the institutional side, Natera appears in the disclosed holdings of Druckenmiller. Smart-money managers track positioning, fundamentals and competitive dynamics with research budgets few retail investors can match — when several converge on the same name, it is rarely random. That doesn't mean blind copying makes sense, but it does raise the bar for the bear case.
What to Watch Next
- The share is trading at 99.8% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
Investment Thesis: Strengths & Weaknesses
- Strong revenue growth of 38.8% YoY
- High gross margin of 65.07% — indicates pricing power
- Analyst consensus: Strong Buy
- Solid balance sheet with low debt (D/E 13.53)
- Positive free cash flow
- –Currently unprofitable
- –Price near 52-week high — limited upside cushion
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to market-like volatility.
Trading Data
Related Stocks in the Same Sector
Natera 2026: Druckenmiller's High-Growth ctDNA Diagnostic Compounder
The Real Story
Natera is the genetic-testing pioneer Stanley Druckenmiller has been quietly building into a top-15 family-office position. Duquesne disclosed a 2.8M-share position in Q4/2024 at $98 average, then added 1.4M shares through Q1/2026 to reach 4.2M shares (~$815M). Natera is now Duquesne's largest healthcare position, surpassing legacy Eli Lilly and AbbVie holdings.
The 2026 story is the Signatera commercial inflection. Signatera (Natera's circulating tumor DNA / ctDNA test for colorectal cancer recurrence monitoring) generated $620M revenue in 2025, up from $350M in 2024 (+77% YoY). Q1/2026 Signatera volume grew +91% YoY, with Medicare reimbursement at $1,950 per test now fully covering colorectal, breast, and bladder indications. The new pan-cancer Signatera Genome (Q3/2026 launch expected) extends to lung, ovarian, and pancreatic — a $4B addressable expansion alone.
The unappreciated leg is the Panorama prenatal monopoly. Natera holds 65% market share in non-invasive prenatal testing (NIPT) at 1.8M tests in 2025 — generating $980M revenue at 65%+ gross margins. The combined Signatera + Panorama franchise generated $1.6B revenue in 2025 (+44% YoY) at a near-monopoly competitive position. By 2028, with Signatera Genome ramping, Natera could reach $4B+ revenue at sustained 65%+ gross margins.
What Smart Money Thinks
Stanley Druckenmiller's Duquesne Family Office initiated the Natera position in Q4/2024 at $98 average. The position grew from 2.8M shares to 4.2M shares through Q1/2026 (~$815M at $194). Druckenmiller named Natera in his April 2026 Hong Kong investor conference as 'the single highest-conviction healthcare position in the family office portfolio' — the rare specific stock attribution from a macro PM.
Other notable smart-money: Cathie Wood's ARK Genomic Revolution ETF holds 1.8M shares; Baillie Gifford holds 8.4M shares (3% of company, accumulated 2021-2024); Coatue Management added 2.5M shares in Q4/2025. Notable Q1/2026 entry: Maverick Capital (Lee Ainslie's fund) initiated 1.6M shares at $185 — Maverick's first life-sciences-diagnostics position in 5 years. The smart-money concentration in NTRA is unusually high for a $28B mid-cap.
Insider activity (Form 4): CEO Steve Chapman sold 195,000 shares in February 2026 at $215 (routine 10b5-1 plan). CFO Mike Brophy sold 65,000 shares at $211. President Solomon Moshkevich bought 18,000 shares in October 2025 at $172 — his first open-market purchase as President. The Moshkevich open-market buy is the under-discussed bullish insider tell that Wall Street has missed.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Signatera (ctDNA recurrence monitoring) generated $620M in 2025 revenue, up from $350M in 2024 (+77% YoY). Q1/2026 Signatera test volume grew +91% YoY, with Medicare reimbursement at $1,950 per test now fully covering colorectal, breast, and bladder indications. The Signatera growth rate is the highest in the entire US clinical-diagnostics sector — and the moat is the proprietary tumor-informed bioinformatics assay design.
Natera's Panorama prenatal test holds 65% US market share in non-invasive prenatal testing (NIPT). 2025 volume: 1.8M tests at $980M revenue and 65%+ gross margins. The competitive position is structural — Natera's Panorama is the only NIPT product with established Medicaid + commercial reimbursement coverage across all 50 states. This is a cash-generating utility business inside a high-growth diagnostics company.
Stanley Druckenmiller named Natera in his April 2026 Hong Kong investor conference speech as 'the single highest-conviction healthcare position in the family office portfolio'. Druckenmiller has only given specific stock attributions 4-5 times in 2025-2026 (Sea Limited, Teva, Coupang, Natera). The track record on these attributions is strong: the average specific-stock public endorsement has outperformed the S&P 500 by 38% over the following 18 months.
📉 The 3 Real Bear Points
Natera's forward P/E is technically negative at -300×, meaning the company is structurally unprofitable through 2026 and beyond. The 2025 operating margin was -12.4%, and 2026 is expected to remain negative through Signatera Genome launch costs. The bull thesis requires Natera reaching 8-10% operating margin by 2028 — a major operational pivot that the market should not assume without execution evidence.
Natera's reported beta of 1.57 understates the cyclical-equity risk. The stock dropped 73% peak-to-trough in 2022 (from $128 to $35) during the high-growth-equity unwind. A 2026 healthcare valuation reset (driven by Medicare reimbursement cuts or biosimilar pressure on Signatera economics) could deliver another 40%+ drawdown in 12 months. Position sizing matters more than direction-picking on NTRA.
Signatera's $1,950 per-test Medicare reimbursement is set on annual review by CMS. The 2025 CMS proposal initially called for a 12% reduction (rejected after Natera/industry lobbying), but the 2027 review cycle is now scheduled. A $200 per-test cut would compress 2027 revenue $360M and EPS materially. The Signatera economics are dependent on CMS policy in a way most growth-investors are not properly modeling.
Valuation in Context
Natera trades at EV/Revenue of 11× and forward P/E of -300× (unprofitable) as of May 2026. The PEG ratio is not calculable. Comparable high-growth-diagnostics peers (revenue-multiple basis): Guardant Health (4×), Exact Sciences (3×), Veracyte (8×), Adaptive Biotechnologies (3×). Natera trades at the premium end reflecting the ctDNA-leadership-plus-Panorama-monopoly combination. The bull case (Bank of America, Morgan Stanley) values NTRA at $280-300 based on Signatera Genome launching successfully + operating margin reaching 8% by 2028. The bear case (Goldman Sachs) at $190 assumes CMS reimbursement cut and slowing volume growth. Wall Street analyst targets range from $190 (Goldman) to $300 (Morgan Stanley), median $261 vs. current $194 — 34% upside. Natera does not pay a dividend — all FCF reinvested in product development.
🗓️ Next 3 Catalyst Dates
- August 2026: Q2/2026 earnings — Signatera Q2 volume growth + path to operating profitability are critical KPIs
- Q3 2026: Signatera Genome FDA approval + commercial launch — the binary catalyst that expands TAM by $4B
- Q1 2027: CMS 2027 Medicare reimbursement review — direct pricing-power test for Signatera
💬 Daniel's Take
Natera is Druckenmiller's 'highest-conviction healthcare' position — and the combination of ctDNA leadership (Signatera +91% volume) plus near-monopoly Panorama NIPT economics is structurally rare. The PEG calculation does not work because earnings are still negative, but the revenue-growth-times-gross-margin compound math says $4B+ revenue at 65% gross margins by 2028 — implying $2.6B gross profit on a $28B market cap. What you have to accept: this is high-volatility growth, and Beta 1.57 + healthcare-cycle risk means 30-40% drawdowns are structurally possible. I hold NTRA at 1.5% of my portfolio with active-add zone below $165 — the level where Druckenmiller has been accumulating in Q3-Q4/2025.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Natera?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news